Here's Why You Should Hold Stryker Stock in Your Portfolio for Now

Stryker posted 9.0% organic sales growth in Q2 2026 and adjusted EPS growth of 17.9% to $3.69, with gross margin up 60bps to 66.0% and operating margin up 170bps to 27.4%. Mako robotics adoption exceeded 2.5 million procedures across 47 countries, supporting growth in orthopaedics and recurring implant and instrument demand. However, cybersecurity remediation, Peripheral Vascular supply disruption worth an estimated 50-75bps drag on organic growth, and potentially nonrecurring tariff benefits create execution and margin risks; management maintained full-year adjusted EPS guidance of $14.95-$15.10.

Analysis

SYK’s investable issue is not demand but earnings-quality: the current margin trajectory embeds a mix of genuine operating leverage and transitory cost relief, while remediation and factory normalization remain variable costs. That creates an asymmetric next-quarter setup—revenue can meet expectations while EPS disappoints if the temporary benefit rolls off before utilization fully normalizes. The key diligence item is incremental gross margin on recovered vascular volume; a clean recovery should convert backlog into an earnings tailwind in the next 1-3 months, whereas further slippage would expose the fragility of consensus EPS assumptions.

Mako’s strategic value is the consumables and implant pull-through rather than capital-system revenue. Wider procedure coverage raises surgeon and hospital switching costs, pressuring orthopedic competitors such as ZBH and JNJ/DePuy even if they retain accounts through pricing. Over 6-18 months, this can support a premium multiple only if procedure growth translates into accelerating recurring revenue per installed system; otherwise the market will treat the platform expansion as capital-equipment spend with lower-quality growth.

The contrarian view is that SYK’s drawdown may already discount operational disruption, but not a sustained de-rating if management cannot separate structural productivity from tariff and recovery noise. GMED offers a cleaner near-term execution expression in musculoskeletal technology, though its repeated beats likely leave less room for error. ABT is a lower-beta alternative for healthcare exposure but lacks the same robotics-driven operating leverage.

Key Decisions for Investors

• Maintain SYK as a watch-to-buy rather than add aggressively before the next results: initiate only if management confirms vascular backlog normalization and reiterates EPS guidance without widening the range. Target a 3-6 month rerating on clean conversion; exit if organic growth decelerates below mid-single digits or adjusted operating margin fails to hold near 27%.
• Pair trade for the next 1-3 months: long GMED / short SYK in equal dollar exposure. GMED has the cleaner estimate-beat setup, while SYK carries manufacturing-recovery and margin-quality risk; close the spread if SYK demonstrates backlog recovery with sequential gross-margin expansion.
• For existing SYK longs, use a defined-risk hedge into earnings via a 1-3 month put spread, sized against the position rather than as a standalone volatility trade. The hedge is justified by guidance-range risk and should be removed if supply-chain KPIs normalize before the event.
• Do not act on VCYT, ABT, or QBTS from this item alone. Their cited fundamentals do not establish a direct transmission mechanism from SYK’s execution, robotics adoption, or supply-chain outcomes.